Helus Pharma Appoints Michael Cola as CEO
Helus Pharma announced the appointment of Michael Cola as Chief Executive Officer, effective immediately. Cola's appointment comes at a moment as Helus advances its pipeline of next-generation mental health therapies toward key clinical and corporate value-inflection milestones, including the expected release of Phase 2 data for HLP004 this quarter and Phase 3 topline data for HLP003 in Q4 2026. Cola was formerly President of Shire's Specialty Pharmaceutical business
